Exosomal PD-L1 can be a major regulator of tumor progression through its ability to suppress T-cell activation, suggesting that targeting both cell-surface and exosome PD-L1 presentation could be a novel therapeutic strategy [85,86]. The gene discussed is CD274; the disease is neoplasm.